Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Convulsant actions of calycanthine.

Mary Chebib1, Rujee K Duke, Colin C Duke

  • 1Faculty of Pharmacy, The University of Sydney, New South Wales, 2006, Australia.

Toxicology and Applied Pharmacology
|July 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Add-on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss-of-function γ-aminobutyric acid type A receptor variants.

Epilepsia·2026
Same author

A synonymous SLC2A1 variant causes familial epilepsy and paroxysmal exercise-induced dyskinesia by creating aberrant mosaic splicing patterns.

Neurobiology of disease·2026
Same author

Collapse of feed-forward inhibition underpins hyperexcitability in GABAA gain-of-function epilepsy.

Brain : a journal of neurology·2026
Same author

Erratum to 'The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist' [Eur. J. Med. Chem. 210 (2021) 113087].

European journal of medicinal chemistry·2026
Same author

Medicinal Chemistry in the Royal Australian Chemical Institute: The Early Years.

ChemMedChem·2026
Same author

Predictive value of seizure onset for gross motor dysfunction in individuals with pathogenic GABRB2 and GABRB3 variants.

Epilepsia·2026

Calycanthine, a plant alkaloid, acts as a central convulsant by inhibiting GABA release and blocking GABA-A receptors. It also affects calcium channels, contributing to its convulsant effects.

Area of Science:

  • Neuropharmacology
  • Natural Products Chemistry

Background:

  • Calycanthine is a principal alkaloid from the Calycanthaceae family.
  • It is known for its central convulsant properties.

Purpose of the Study:

  • To investigate the neuropharmacological mechanisms underlying calycanthine's convulsant action.
  • To determine the specific neurotransmitter systems and ion channels affected by calycanthine.

Main Methods:

  • Assessed the effect of calycanthine on the release of radiolabeled neurotransmitters (GABA, acetylcholine, D-aspartate, glycine) from brain slices.
  • Examined calycanthine's effects on L-type and N-type calcium currents in neuroblastoma X glioma cells.
  • Investigated calycanthine's direct interaction with GABA-A and GABA-C receptors expressed in Xenopus oocytes.

Related Experiment Videos

Main Results:

  • Calycanthine inhibited potassium-stimulated GABA release from rat hippocampus (ED(50) ≈ 21 μM).
  • It showed moderate selectivity, weakly affecting acetylcholine release and not significantly impacting D-aspartate or glycine release.
  • Calycanthine blocked L-type calcium currents (IC(50) ≈ 42 μM) and weakly inhibited N-type calcium currents.
  • Direct inhibition of GABA-A receptor-mediated currents was observed (K(B) ≈ 135 μM), with no effect on GABA-C receptors.

Conclusions:

  • Calycanthine's convulsant activity is likely mediated by inhibiting GABA release via L-type calcium channel interactions.
  • Direct inhibition of GABA-A receptors further contributes to its convulsant effects.
  • These findings elucidate the neurochemical basis of calycanthine's action.